Neurocrine Biosciences: Growth Beyond Just Ingrezza (NASDAQ:NBIX)

As we move through the first quarter of 2026, I am optimistic about Neurocrine Biosciences ( NBIX ) because they have been able to demonstrate the success of their business development strategy in 2025. They were ableI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My approach is a mix of fundamental analysis and future trend pred ...